-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Reiterates Neutral on Capricor Therapeutics, Raises Price Target to $10.5

Benzinga·11/13/2026 14:55:29
Listen to the news
Roth Capital analyst Boobalan Pachaiyappan reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Neutral and raises the price target from $7 to $10.5.